{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T07:47:42Z","timestamp":1785916062299,"version":"3.56.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T00:00:00Z","timestamp":1712707200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","atherosclerosis-journal.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.atherosclerosis.2024.117529","type":"journal-article","created":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T16:58:42Z","timestamp":1711385922000},"page":"117529","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Inhibition of PCSK9 with evolocumab modulates lipoproteins and monocyte activation in high-risk ASCVD subjects"],"prefix":"10.1016","volume":"392","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5599-0633","authenticated-orcid":false,"given":"Robert S.","family":"Rosenson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Tate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phyu","family":"Mar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Grushko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinzhong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sascha N.","family":"Goonewardena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.atherosclerosis.2024.117529_bib1","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1161\/CIRCULATIONAHA.118.034645","article-title":"Residual inflammatory risk on treatment with pcsk9 inhibition and statin therapy","volume":"138","author":"Pradhan","year":"2018","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.atherosclerosis.2024.117529_bib2","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2024.117529_bib3","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1161\/CIRCULATIONAHA.118.034032","article-title":"Inflammatory and cholesterol risk in the fourier trial","volume":"138","author":"Bohula","year":"2018","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.atherosclerosis.2024.117529_bib4","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1093\/eurheartj\/ehaa1034","article-title":"The neutrophil-lymphocyte ratio and incident atherosclerotic events: analyses from five contemporary randomized trials","volume":"42","author":"Adamstein","year":"2021","journal-title":"Eur. Heart J."},{"issue":"8","key":"10.1016\/j.atherosclerosis.2024.117529_bib5","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1056\/NEJMoa1809798","article-title":"Low-dose methotrexate for the prevention of atherosclerotic events","volume":"380","author":"Ridker","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2024.117529_bib6","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1093\/eurheartj\/ehv637","article-title":"Prognostic value of pcsk9 levels in patients with acute coronary syndromes","volume":"37","author":"Gencer","year":"2015","journal-title":"Eur. Heart J."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2024.117529_bib7","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1159\/000442976","article-title":"Increased plasma pcsk9 levels are associated with reduced endotoxin clearance and the development of acute organ failures during sepsis","volume":"8","author":"Boyd","year":"2016","journal-title":"J. Innate Immun."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2024.117529_bib8","doi-asserted-by":"crossref","first-page":"E732","DOI":"10.1210\/jc.2012-4236","article-title":"Plasma pcsk9 is a late biomarker of severity in patients with severe trauma injury","volume":"98","author":"Le Bras","year":"2013","journal-title":"J. Clin. Endocrinol. Metabol."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2024.117529_bib9","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jacc.2022.10.030","article-title":"Pcsk9 inhibition during the inflammatory stage of sars-cov-2 infection","volume":"81","author":"Navarese","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2024.117529_bib10","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.atherosclerosis.2014.04.001","article-title":"Association of plasma pcsk9 levels with white blood cell count and its subsets in patients with stable coronary artery disease","volume":"234","author":"Li","year":"2014","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2024.117529_bib11","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.jacc.2018.04.054","article-title":"The evolving future of pcsk9 inhibitors","volume":"72","author":"Rosenson","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"issue":"11","key":"10.1016\/j.atherosclerosis.2024.117529_bib12","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1161\/CIRCRESAHA.121.320056","article-title":"Proprotein convertase subtilisin\/kexin 9 (pcsk9) promotes macrophage activation via ldl receptor-independent mechanisms","volume":"131","author":"Katsuki","year":"2022","journal-title":"Circ. Res."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2024.117529_bib13","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1194\/jlr.M003566","article-title":"Strong induction of pcsk9 gene expression through hnf1alpha and srebp2: mechanism for the resistance to ldl-cholesterol lowering effect of statins in dyslipidemic hamsters","volume":"51","author":"Dong","year":"2010","journal-title":"J. Lipid Res."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2024.117529_bib14","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1038\/s41598-018-20425-x","article-title":"Pcsk9 induces a pro-inflammatory response in macrophages","volume":"8","author":"Ricci","year":"2018","journal-title":"Sci. Rep."},{"issue":"20","key":"10.1016\/j.atherosclerosis.2024.117529_bib15","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1093\/eurheartj\/ehx002","article-title":"Pcsk9 monoclonal antibodies reverse the pro-inflammatory profile of monocytes in familial hypercholesterolaemia","volume":"38","author":"Bernelot Moens","year":"2017","journal-title":"Eur. Heart J."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2024.117529_bib16","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1007\/s10237-019-01282-7","article-title":"The importance of blood rheology in patient-specific computational fluid dynamics simulation of stenotic carotid arteries","volume":"19","author":"Mendieta","year":"2020","journal-title":"Biomech. Model. Mechanobiol."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2024.117529_bib17","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0021-9150(98)00144-0","article-title":"Effects of lipids and lipoproteins on thrombosis and rheology","volume":"140","author":"Rosenson","year":"1998","journal-title":"Atherosclerosis"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2024.117529_bib18","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1373\/clinchem.2014.232918","article-title":"Glyca: a composite nuclear magnetic resonance biomarker of systemic inflammation","volume":"61","author":"Otvos","year":"2015","journal-title":"Clin. Chem."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2024.117529_bib19","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3233\/CH-2009-1202","article-title":"New guidelines for hemorheological laboratory techniques","volume":"42","author":"Baskurt","year":"2009","journal-title":"Clin. Hemorheol. Microcirc."},{"key":"10.1016\/j.atherosclerosis.2024.117529_bib20","doi-asserted-by":"crossref","DOI":"10.1161\/ATVBAHA.123.319272","article-title":"Effect of pcsk9 inhibition on the plasma proteome: a spire substudy","author":"Kraaijenhof","year":"2023","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2024.117529_bib21","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1161\/JAHA.116.003822","article-title":"Circulating n-linked glycoprotein side-chain biomarker, rosuvastatin therapy, and incident cardiovascular disease: an analysis from the jupiter trial","volume":"5","author":"Akinkuolie","year":"2016","journal-title":"J. Am. Heart Assoc."},{"issue":"18","key":"10.1016\/j.atherosclerosis.2024.117529_bib22","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"10.1016\/j.atherosclerosis.2024.117529_bib23","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.atherosclerosis.2024.117529_bib24","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1161\/01.CIR.98.9.839","article-title":"Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events (care) investigators","volume":"98","author":"Ridker","year":"1998","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2024.117529_bib25","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa042378","article-title":"C-reactive protein levels and outcomes after statin therapy","volume":"352","author":"Ridker","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"9670","key":"10.1016\/j.atherosclerosis.2024.117529_bib26","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/S0140-6736(09)60447-5","article-title":"Reduction in c-reactive protein and ldl cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the jupiter trial","volume":"373","author":"Ridker","year":"2009","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2024.117529_bib27","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1161\/CIRCRESAHA.118.313238","article-title":"Cholesterol-lowering agents","volume":"124","author":"Rosenson","year":"2019","journal-title":"Circ. Res."},{"issue":"42","key":"10.1016\/j.atherosclerosis.2024.117529_bib28","doi-asserted-by":"crossref","first-page":"4309","DOI":"10.1093\/eurheartj\/ehab465","article-title":"Impact of cholesterol on proinflammatory monocyte production by the bone marrow","volume":"42","author":"Stiekema","year":"2021","journal-title":"Eur. Heart J."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2024.117529_bib29","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1074\/jbc.M209634200","article-title":"Minimally modified ldl binds to cd14, induces macrophage spreading via tlr4\/md-2, and inhibits phagocytosis of apoptotic cells","volume":"278","author":"Miller","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2024.117529_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2023.06.971","article-title":"Evidence of anti-inflammatory effect of pcsk9 inhibitors within the human atherosclerotic plaque","author":"Marfella","year":"2023","journal-title":"Atherosclerosis"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2024.117529_bib31","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1007\/s00125-019-4856-7","article-title":"Efficacy and safety of evolocumab in individuals with type 2 diabetes mellitus: primary results of the randomised controlled banting study","volume":"62","author":"Rosenson","year":"2019","journal-title":"Diabetologia"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2024.117529_bib32","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1111\/dom.13680","article-title":"Randomised study of evolocumab in patients with type 2 diabetes and dyslipidaemia on background statin: primary results of the berson clinical trial","volume":"21","author":"Lorenzatti","year":"2019","journal-title":"Diabetes Obes. Metabol."},{"issue":"9","key":"10.1016\/j.atherosclerosis.2024.117529_bib33","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1161\/CIRCULATIONAHA.121.057807","article-title":"Apolipoprotein b, residual cardiovascular risk after acute coronary syndrome, and effects of alirocumab","volume":"146","author":"Hagstr\u00f6m","year":"2022","journal-title":"Circulation"},{"issue":"1\u20132","key":"10.1016\/j.atherosclerosis.2024.117529_bib34","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0021-9150(81)90107-6","article-title":"Effects of lipoproteins on plasma viscosity","volume":"38","author":"Seplowitz","year":"1981","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2024.117529_bib35","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0021-9150(77)90196-4","article-title":"Studies of plasma viscosity in primary hyperlipoproteinaemia","volume":"28","author":"Leonhardt","year":"1977","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2024.117529_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.109180","article-title":"Association of total vldl particle concentrations with elevated blood viscosity in patients with type 2 diabetes","volume":"183","author":"Rosenson","year":"2022","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2024.117529_bib37","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0021-9150(98)00144-0","article-title":"Effects of lipids and lipoproteins on thrombosis and rheology","volume":"140","author":"Rosenson","year":"1998","journal-title":"Atherosclerosis"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915024000893?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915024000893?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,19]],"date-time":"2024-05-19T15:58:46Z","timestamp":1716134326000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915024000893"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":37,"alternative-id":["S0021915024000893"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2024.117529","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibition of PCSK9 with evolocumab modulates lipoproteins and monocyte activation in high-risk ASCVD subjects","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2024.117529","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"117529"}}